Menu
PRESS RELEASES
REPORTS
SpectraCure is developing the future system for the treatment of prostate cancer. Our vision is to eliminate internal cancer tumors and improve both survival rates and quality of life.
SpectraCures system is suitable for the treatment of internal tumors in, for example, the prostate, breast, pancreas or head and neck region. As a first indication, we have chosen to address recurrent prostate cancer. This is because there is currently no treatment that is both effective and has few side effects for prostate cancer recurrence. Often a lifelong treatment with hormonal therapy is prescribed.
Our method is based on photodynamic therapy (PDT), which means that a light-activated drug is used to make the tissue sensitive to light. The drug is then activated by laser which eliminates the cancer cells.
We are currently running a clinical trial for patients with recurrent prostate cancer in the United States, the United Kingdom and Canada. The aim of the trail is to investigate the effect of the treatment and to determine the most effective light dose in combination with the drug verteporfin.
Recurrent prostate cancer can be difficult to treat. For example, after radiotherapy, surgical removal of the prostate is difficult, and the operation carries a significant risk of side effects. The most common treatment offered is hormone therapy, which is also associated with significant side effects. Therefore SpectraCure has chosen recurrent prostate cancer as the first indication. Our ambition is to offer patients with recurrent prostate cancer an effective treatment with few side effects, and the potential for a good quality of life.
The treatment method, interstitial PDT, is enabled by an entirely new generation of treatment systems that include both dose planning and delivery of laser light. The integrated IDOSE® software calculates and adapts the laser exposure for each patient. This is important because overexposure to laser light can lead to damage to healthy tissue. In turn, underexposure can lead to incomplete treatment and recurrence of the tumor after treatment.
For a tomorrow where we cure cancer and improve quality of life for those affected
investor
Global market with high growth
A real clinical need
A new treatment option
Health economic viability
Attractive business model with continuous revenue streams
Potential to develop treatment for more cancer diagnoses
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.